

Remarks

Currently Claims 1-32 are pending.

The specification is amended to include an abstract on a separate page and to recite cross-reference to related applications.

Claims 33-40 are canceled for the purpose of reducing claim fees. Claims 4-21, 23, 25-26 and 28-32 are amended to remove multiple dependencies for the purpose of reducing claim fees. Applicants expressly reserve the right to file one or more continuation applications directed toward the subject matter of the original claims. The amendments do not narrow the scope of the claims. No new matter is added.

Applicants respectfully submit that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at (919) 483-8222, to discuss this case, if desired.

Respectfully submitted,



Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

Date: 8 July, 2004
GlaxoSmithKline Inc.
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222
fax: (919) 483-7988
lorie.a.morgan@gsk.com